InflaRx

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell InflaRx and other ETFs, options, and stocks.

About IFRX

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. 

CEO
Niels Christoph Riedemann
CEONiels Christoph Riedemann
Employees
74
Employees74
Headquarters
Jena, Thueringen
HeadquartersJena, Thueringen
Founded
2007
Founded2007
Employees
74
Employees74

IFRX Key Statistics

Market cap
84.59M
Market cap84.59M
Price-Earnings ratio
-1.18
Price-Earnings ratio-1.18
Dividend yield
Dividend yield
Average volume
14.38M
Average volume14.38M
High today
$1.40
High today$1.40
Low today
$1.24
Low today$1.24
Open price
$1.36
Open price$1.36
Volume
1.67M
Volume1.67M
52 Week high
$2.82
52 Week high$2.82
52 Week low
$0.7113
52 Week low$0.7113

Stock Snapshot

With a market cap of 84.59M, InflaRx(IFRX) trades at $1.26. The stock has a price-to-earnings ratio of -1.18.

During the trading session on 2025-11-18, InflaRx(IFRX) shares reached a daily high of $1.40 and a low of $1.24. At a current price of $1.26, the stock is +1.6% higher than the low and still -10.0% under the high.

Trading volume for InflaRx(IFRX) stock has reached 1.67M, versus its average volume of 14.38M.

Over the past 52 weeks, InflaRx(IFRX) stock has traded between a high of $2.82 and a low of $0.71.

Over the past 52 weeks, InflaRx(IFRX) stock has traded between a high of $2.82 and a low of $0.71.

IFRX News

TipRanks 6d
Cautious Hold Rating for InflaRx’s INF904 Amid Uncertainties in Trial Results

LifeSci Capital analyst Sam Slutsky has maintained their neutral stance on IFRX stock, giving a Hold rating yesterday. Meet Your ETF AI Analyst Discover how Tip...

TipRanks 7d
InflaRx price target raised to $9 from $2 at Raymond James

Raymond James analyst Ryan Deschner raised the firm’s price target on InflaRx (IFRX) to $9 from $2 and keeps an Outperform rating on the shares. Inflarx reporte...

Analyst ratings

100%

of 7 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own IFRX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.